Key clinical point: For patients with relapsed/refractory chronic lymphocytic leukemia, long-term treatment with idelalisib appears safe and effective.

Major finding: Patients who received a combination of rituximab and idelalisib followed by idelalisib monotherapy had a median overall survival of 40.6 months.

Study details: A randomized, double-blind, phase 3 trial involving patients with relapsed/refractory chronic lymphocytic leukemia.

Disclosures: Gilead Sciences funded the study. Dr. Sharman reported financial relationships with Gilead and other companies.